2P4.F - BioPorto A/S

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.1958
+0.0012 (+0.62%)
At close: 08:09AM CEST
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.1946
Open0.1958
Bid0.1956 x 0
Ask0.2225 x 0
Day's Range0.1958 - 0.1958
52 Week Range0.1072 - 0.3800
Volume1,000
Avg. Volume771
Market Cap71.412M
Beta (5Y Monthly)1.46
PE Ratio (TTM)N/A
EPS (TTM)-0.0300
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 2P4.F

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      BioPorto A/S initiates a rights issue with pre-emptive rights for its existing shareholders and proceeds of up to approximately DKK 59.4 million with approximately DKK 16.6 million pre-subscribed pursuant to advance commitments

      May 30, 2023Announcement no. 10 THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE, OR A SOLICITATION OF AN OFFER TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY SECURITIES IN THE UNITED STATES (INCLUDING ITS TERRITORIES AND

    • GlobeNewswire

      Increase in share capital following exercise of warrants – Notice of changes in share capital and voting rights pursuant to section 32 of the Danish Capital Markets Act

      May 23, 2023Announcement no. 9 Increase in share capital following exercise of warrants – Notice of changes in share capital and voting rights pursuant to section 32 of the Danish Capital Markets Act COPENHAGEN, DENMARK and BOSTON, MA, USA, May 23, 2023, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) hereby announces that the Company’s share capital has been increased by nominally DKK 2,000,000, corresponding to 2,000,000 new shares, as a result of t

    • GlobeNewswire

      BioPorto Announces Interim Results for the First Three Months of 2023

      May 10, 2023Announcement no. 8 BioPorto Announces Interim Results for the First Three Months of 2023 COPENHAGEN, Denmark and BOSTON, MA, USA, May 10, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced interim financial results for the first three months of 2023 and business progress for the first quarter of 2023. Recent Highlights For the three months ended March 31, 2023: Total revenue of DKK 8.0 million / USD 1.2 million, a 24% increase over the prior yearAdjusted E

    • GlobeNewswire

      BioPorto A/S to Host Quarterly Earnings Webcast and Analyst Call

      May 3, 2023News release BioPorto A/S to Host Quarterly Earnings Webcast and Analyst Call COPENHAGEN, DENMARK and BOSTON, MA, USA, May 3, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today that, in connection with the release of its Interim Report for the first quarter of 2023, the Company’s management team will host an online investor presentation on May

    • GlobeNewswire

      Resolutions of the General Meeting of BioPorto A/S

      April 27, 2023Announcement no. 07 Resolutions of the General Meeting of BioPorto A/S COPENHAGEN, DENMARK and BOSTON, MA, USA, April 27, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) today held its General Meeting with the following results: 1) The Board's report on the Company’s activities for the past year was noted by the General Meeting. 2) The annual report was approved by the General Meeting and the result for the financial year 2022 was approved to be carried fo

    • GlobeNewswire

      Grant of Warrants

      April 25, 2023Announcement no. 6 Grant of Warrants COPENHAGEN, DENMARK and BOSTON, MA, USA, April 25, 2023, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has, in accordance with its current authorization, today issued 4,987,721 warrants to the executive management of BioPorto for the subscription of an equal number of shares. The warrants are issued in accordance with the Company’s remuneration policy and the authorization in section 18 a of

    • GlobeNewswire

      Notice convening the Annual General Meeting in BioPorto A/S

      April 5, 2023Announcement no. 5 Notice convening the Annual General Meeting in BioPorto A/S The Board of Directors hereby convenes the Annual General Meeting of BioPorto A/S (“BioPorto” or the “Company”) to be held on: Thursday April 27, 2023, at 3.00 p.m. (CEST)At the Company’s addressTuborg Havnevej 15, st., DK-2900 Hellerup, Denmark AGENDA: ITEM 1 - REPORT ON THE COMPANY’S ACTIVITIES DURING THE PAST YEAR The Board of Directors proposes that the Board's report on the Company’s activities for t

    • GlobeNewswire

      BioPorto Announces Annual Results for the Year ended December 31, 2022

      March 30, 2023Announcement no. 4 BioPorto Announces Annual Results for the Year ended December 31, 2022 COPENHAGEN, Denmark and BOSTON, MA, USA, March 30, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced financial results for the year ended December 31, 2022 and business progress for the fourth quarter of 2022. Recent Highlights For the year ended December 31, 2022: Total revenue of DKK 29.0 million / USD 4.1 million, a 19% increase over the prior yearAdjusted EBITD

    • GlobeNewswire

      BioPorto Announces Financial Guidance for 2023

      March 29, 2023Announcement no. 3 BioPorto Announces Financial Guidance for 2023 COPENHAGEN, Denmark and BOSTON, MA, USA, March 29, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) announces financial guidance for 2023. BioPorto’s three strategic activities in 2023 are to: Grow revenues in European and other markets that accept CE MarkFocus on the US NGAL test’s regulatory pathwayExpand the total addressable market for NGAL tests Key assumptions relating to the 2023 outlo

    • GlobeNewswire

      US healthcare executive Dr. Ninfa Saunders, DHA, MVA, MSN, FACHE and other Board members to be nominated at general meeting; Chris Lindop not standing for re-election.

      March 29, 2023Announcement no. 2 US healthcare executive Dr. Ninfa Saunders, DHA, MVA, MSN, FACHE and other Board members to be nominated at general meeting; Chris Lindop not standing for re-election. COPENHAGEN, DENMARK and BOSTON, MA, USA, March 29, 2023, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) announces that Chris Lindop, Chairman of the Board of Directors, has for personal reasons decided not to stand for re-election at the upcoming ordina

    • GlobeNewswire

      BioPorto A/S to Host Annual Earnings Webcast and Analyst Call

      March 23, 2023News release BioPorto A/S to Host Annual Earnings Webcast and Analyst Call COPENHAGEN, DENMARK and BOSTON, MA, USA, March 23, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today that, in connection with the release of its 2022 Annual Report, the Company’s management team will host an online investor presentation on March 30, 2023 at 14:30 Ce

    • GlobeNewswire

      BioPorto Provides a Business Update

      March 15, 2023News release BioPorto Provides a Business Update COPENHAGEN, DENMARK and BOSTON, MA, March 15, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) today provided a business update. Preliminary key 2022 Financial ResultsRevenue for the full year 2022 is expected to be approximately DKK 29.0 million, which represents a 19% increase over the prior year and exceeds the upper end of the Company’s most recent guidance by 7%. Cash and cash equivalents are estimated to

    • GlobeNewswire

      BioPorto adds Dr. Tabari Baker as VP of Global Medical Affairs

      February 14, 2023News Release BioPorto adds Dr. Tabari Baker as VP of Global Medical Affairs COPENHAGEN, DENMARK and BOSTON, MA, February 14, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) today announced the addition of Dr. Tabari Baker as Vice President of Global Medical Affairs. In this role, Dr. Baker will lead BioPorto’s medical and scientific support for NGAL tests and build upon its strong relationships with key industry stakeholders. “Expanding market awareness

    • GlobeNewswire

      Financial Calendar 2023

      December 30, 2022Announcement no. 19 Financial Calendar 2023 COPENHAGEN, DENMARK and BOSTON, MA, USA, December 30, 2022, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) hereby publishes its Financial Calendar for 2023: 2023 Key Dates March 15, 2023Deadline for shareholder proposals – Annual General MeetingMarch 30, 2023Annual Report 2022April 27, 2023Annual General MeetingMay 10, 2023Interim Report – for the three-month period ended March 31, 2023August 1, 2023Interim Report –

    • GlobeNewswire

      BioPorto adds Mr. Nis Kruse as EVP of Strategic Partnerships and GM of EMEA & APAC

      COPENHAGEN, Denmark and BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) today announced that Mr. Nis Kruse joined the Company as EVP of Strategic Partnerships and General Manager of EMEA & APAC. He will also serve as site leader for the Hellerup, Denmark office. “We are preparing for the prospective global launch of NGAL tests, having submitted our De Novo application to the US Food and Drug Administration to aid in identifying pediatric patients at risk

    • GlobeNewswire

      Resolutions of the Extraordinary General Meeting of BioPorto A/S

      November 23, 2022 Announcement no. 17 Resolutions of the Extraordinary General Meeting of BioPorto A/S COPENHAGEN, DENMARK and BOSTON, MA, USA, November 23, 2022, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) today held an Extraordinary General Meeting with the following results: Deloitte Statsautoriseret Revisionspartnerselskab, company registration number 33963556, was elected as the Company’s new auditor.The chair of the general meeting, with a right of substitution, was

    • GlobeNewswire

      Correction: BioPorto Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration

      November 10, 2022 Announcement no. 16 BioPorto Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration COPENHAGEN, DENMARK and BOSTON, MA, USA, November 10, 2022, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) has announced the submission of a De Novo application to the US Food and Drug Administration (FDA) of a neutrophil gelatinase-associated lipocalin (NGAL) test to aid in identifying pediatric patients (≥3 months to <22 years)

    • GlobeNewswire

      BioPorto Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration

      November 10, 2022 Announcement no. 16 BioPorto Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration COPENHAGEN, DENMARK and BOSTON, MA, USA, November 10, 2022, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) has announced the submission of a De Novo application to the US Food and Drug Administration (FDA) of a neutrophil gelatinase-associated lipocalin (NGAL) test to aid in identifying pediatric patients (≥3 months to <22 years)

    • GlobeNewswire

      BioPorto Announces Interim Results for the First Nine Months of 2022

      Announcement no. 15 COPENHAGEN, Denmark and BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced interim financial results for the first nine months of 2022 and business progress for the third quarter of 2022. Recent Highlights For the nine months ending September 30, 2022: Total revenue of DKK 20.3 million / USD 2.9 million, a 16% increase over the prior yearAdjusted EBITDA of DKK (49.5) million / USD (7.2) millionCash and cash equivalents of DKK 98.9 m

    • GlobeNewswire

      NOTICE CONVENING THE EXTRAORDINARY GENERAL MEETING

      November 1, 2022 Announcement no. 14 NOTICE CONVENING THE EXTRAORDINARY GENERAL MEETING In accordance with Article 5 of the Articles of Association, the Board of Directors hereby convenes an Extraordinary General Meeting of BioPorto A/S (the “Company”): November 23, 2022, at 9.00 am (CET), At the Company’s address Tuborg Havnevej 15, st., DK-2900 Hellerup (Parking available in nearby Waterfront Shopping Center) As the duration of the meeting is expected to be short, shareholders are encouraged t

    • GlobeNewswire

      Update: BioPorto Exhibiting NGAL Biomarker at ASN Kidney Week – Antibodies, ELISA kits, and Clinical Chemistry Assays for Early Drug Development and Clinical Research

      October 27, 2022 Press release BioPorto Exhibiting NGAL Biomarker at ASN Kidney Week – Antibodies, ELISA kits, and Clinical Chemistry Assays for Early Drug Development and Clinical Research COPENHAGEN, DENMARK and BOSTON, MA, USA, October 27, 2022, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced it will showcase its NGAL biomarker for acute kidney injury (AKI) research (clinical chemistry assay, ELISA kits, and antibodies) at booth #2734 during the world’s premiere nephr

    • GlobeNewswire

      BioPorto Exhibiting NGAL Biomarker at ASN Kidney Week – Antibodies, ELISA kits, and Clinical Chemistry Assays for Early Drug Development and Clinical Research

      October 27, 2022 Press release BioPorto Exhibiting NGAL Biomarker at ASN Kidney Week – Antibodies, ELISA kits, and Clinical Chemistry Assays for Early Drug Development and Clinical Research COPENHAGEN, DENMARK and BOSTON, MA, USA, October 24, 2022, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced it will showcase its NGAL biomarker for acute kidney injury (AKI) research (clinical chemistry assay, ELISA kits, and antibodies) at booth #2734 during the world’s premiere nephr

    • GlobeNewswire

      BioPorto to Participate in H.C. Wainwright’s 24th Annual Global Investment Conference

      COPENHAGEN, Denmark and BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced plans to participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022 in New York City. Following are details for management’s presentation: Date: September 12, 2022 Time: Available On Demand at 7am ET Webcast Link: https://journey.ct.events/view/2785e18a-7a71-4dd6-a735-695045a60f04 Management will also be available for 1x1 meet

    • GlobeNewswire

      BioPorto Announces Interim Results for the First Six Months of 2022

      August 17, 2022Announcement no. 13 BioPorto Announces Interim Results for the First Six Months of 2022 COPENHAGEN, DENMARK and BOSTON, MA, USA, August 17, 2022, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced interim financial results for the first six months of 2022 and business progress for the second quarter of 2022. Recent Highlights For the six months ending June 30, 2022: Total revenue of DKK 15.0 million / USD 2.2 million, a 23% increase over the prior yearAdjuste

    • GlobeNewswire

      BioPorto Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S.

      COPENHAGEN, Denmark and BOSTON, June 28, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced its achievement of targeted subject enrollment for the third part of a 3-part clinical study to support a U.S. Food and Drug Administration (FDA) De Novo submission for use of The NGAL Test in identifying patients under the age of 22 at risk for Acute Kidney Injury (AKI). “We are very pleased to have reached the study’s planned enrollment of 600 patients by the end of Q2, as pre